Home > Products > Biosimilars

BioSIM anti-Human FGF23 Antibody (Burosumab Biosimilar), Research Grade

Catalog: SIM0584
Cost advantage to: SIM0079
Product Details Specifications Application References Related Products

Product Details

This biosimilar has the same variable regions as therapeutic antibody Burosumab, ideal for research. Burosumab (fully human IgG1 mAb) targets FGF-23, blocking its FGFR1–α-Klotho binding to restore phosphate homeostasis. Clinically approved for adult/child XLH and TIO, it boosts serum phosphate, improves bone health, with sustained efficacy/safety. The biosimilar suits studying phosphate/vitamin D metabolism, FGF signaling, bone biology, and FGF-23 blockade.
 

Specifications

Product Name BioSIM anti-Human FGF23 Antibody (Burosumab Biosimilar), Research Grade
Size 1mg/5mg
Isotype /
Target FGF23
Other Names KRN-23, UX-023, CAS: 1610833-03-8
CAS 1610833-03-8
Reactivity Human
Host Species Human
Background This biosimilar has the same variable regions as therapeutic antibody Burosumab, ideal for research. Burosumab (fully human IgG1 mAb) targets FGF-23, blocking its FGFR1–α-Klotho binding to restore phosphate homeostasis. Clinically approved for adult/child XLH and TIO, it boosts serum phosphate, improves bone health, with sustained efficacy/safety. The biosimilar suits studying phosphate/vitamin D metabolism, FGF signaling, bone biology, and FGF-23 blockade.
Applications ELISA, FACS, Functional assay, Research in vivo
Purification Protein A/G
Storage To ensure appropriate storage, Please avoid repeated freeze thaw cycles. Keep the product at 4°C for short-term needs (1–2 weeks); Store at -20°C for up to 12 months.  For long-term storage, store at -80°C.
Shipping 2-8°C with blue ice
Concentration Lot specific, generally ≥ 5.0 mg/ml
Shelf Life 12 months from the date of receipt if stored as recommended
Formulation PBS, pH 7.4, contains no stabilizers or preservatives
Sterility 0.2 μM filtered
Endotoxin ≤ 1.0 EU/mg
Purity 99%

Application References

Related Products